Ultragenyx Pharmaceutical Inc
(NAS:RARE)
$
57.87
1.5 (2.66%)
Market Cap: 5.33 Bil
Enterprise Value: 4.46 Bil
PE Ratio: 0
PB Ratio: 12.33
GF Score: 74/100 
Ultragenyx Pharmaceutical Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019 / 06:10PM GMT
Release Date Price:
$45.01
(+4.36%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome, everyone, to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. Before we start, please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley website at www.morganstanley.com/research disclosures or at the registration desk.
For this session, we have Shalini Sharp, CFO of Ultragenyx. Welcome, Shalini.
Shalini Sharp
Ultragenyx Pharmaceutical Inc. - CFO & Executive VP
Thank you, and thanks for having us today.
Questions & Answers
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Definitely. For those in the room who may not be familiar with Ultragenyx, can you provide a brief introduction?
Shalini Sharp
Ultragenyx Pharmaceutical Inc. - CFO & Executive VP
Sure. So
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers